TrialNature communications2026

Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study.

Feng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.